Wedbush Analyst David Nierengarten reiterated an Outperform rating with a 12-month price target of $1000 for argenx SE (ARGX), a commercial-stage biopharma company.
The company markets VYVGART or Efgartigimod for the treatment of generalised Myasthenia Gravis (gMG) and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
For comments and feedback contact: editorial@rttnews.com
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.